Abstract
The discovery of nonclassical actions, other than mineral homeostasis, of 1α,25- dihydroxyvitamin D3 (1,25D3) has expanded its applications. Among these, its anti-inflammation activity has drawn more and more attention of researchers to investigate its role in regulating the progression of inflammatory diseases. The expression of many inflammation-related genes is regulated by 1,25D3 through vitamin D receptor (VDR) in a large variety of cells including immune cells such as, but not limited to, macrophages, dendritic cells, T helper cells, and B cells. Studies of 1,25D3 in these immune cells have shown both direct and indirect immunomodulatory activities affecting innate and adaptive immune responses. Moreover, 1,25D3 can also exert its anti-inflammation effects through regulating the biosynthesis of pro-inflammatory molecules in the prostaglandin pathway or through nuclear factor kappa light-chain-enhancer of activated B cells (NFκB) by affecting cytokine production and inflammatory responses. These actions of 1,25D3 may explain the associations between vitamin D levels and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, asthma, type 1 diabetes, and systemic lupus erythematosus. Although several analogs of 1,25D3 have shown potent immunomodulatory or anti-inflammatory activity on immune cell cultures or in animal models, no vitamin D analog has been used in clinical research to treat inflammatory diseases. Here, we review the relationship between vitamin D analogs and inflammation based on observations of immune cells, prostaglandin and NFκB pathways, as well as common inflammatory diseases.
Keywords: Analogs, Autoimmune diseases, Immune systems, Inflammatory diseases, Vitamin D, VDR.
Current Topics in Medicinal Chemistry
Title:The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Volume: 16 Issue: 11
Author(s): Zongtao Lin and Wei Li
Affiliation:
Keywords: Analogs, Autoimmune diseases, Immune systems, Inflammatory diseases, Vitamin D, VDR.
Abstract: The discovery of nonclassical actions, other than mineral homeostasis, of 1α,25- dihydroxyvitamin D3 (1,25D3) has expanded its applications. Among these, its anti-inflammation activity has drawn more and more attention of researchers to investigate its role in regulating the progression of inflammatory diseases. The expression of many inflammation-related genes is regulated by 1,25D3 through vitamin D receptor (VDR) in a large variety of cells including immune cells such as, but not limited to, macrophages, dendritic cells, T helper cells, and B cells. Studies of 1,25D3 in these immune cells have shown both direct and indirect immunomodulatory activities affecting innate and adaptive immune responses. Moreover, 1,25D3 can also exert its anti-inflammation effects through regulating the biosynthesis of pro-inflammatory molecules in the prostaglandin pathway or through nuclear factor kappa light-chain-enhancer of activated B cells (NFκB) by affecting cytokine production and inflammatory responses. These actions of 1,25D3 may explain the associations between vitamin D levels and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, asthma, type 1 diabetes, and systemic lupus erythematosus. Although several analogs of 1,25D3 have shown potent immunomodulatory or anti-inflammatory activity on immune cell cultures or in animal models, no vitamin D analog has been used in clinical research to treat inflammatory diseases. Here, we review the relationship between vitamin D analogs and inflammation based on observations of immune cells, prostaglandin and NFκB pathways, as well as common inflammatory diseases.
Export Options
About this article
Cite this article as:
Lin Zongtao and Li Wei, The Roles of Vitamin D and Its Analogs in Inflammatory Diseases, Current Topics in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1568026615666150915111557
DOI https://dx.doi.org/10.2174/1568026615666150915111557 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Understanding the Molecular Aspects of Vitamins in Parkinson’s Disease: Present-day Concepts and Perspectives
Current Pharmaceutical Design Linking Inflammation to Cell Cycle Progression
Current Pharmaceutical Design Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics Evaluation of Hyperforin Analogues for Inhibition of 5-lipoxygenase
Medicinal Chemistry Beta-Adrenergic Antagonists: Indications and Potential Immunomodulatory Side Effects in the Critically Ill
Current Medicinal Chemistry Advancement of Mechanisms of Coxsackie Virus B3-Induced Myocarditis Pathogenesis and the Potential Therapeutic Targets
Current Drug Targets Macrocyclic Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Role and Pharmacogenomics of TNF-α in Asthma
Mini-Reviews in Medicinal Chemistry Central Nervous System-Related
Current Bioactive Compounds Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia
Current Pharmacogenomics Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Current Drug Targets